EichorEICHOR
Condition: Extensive Disease Small Cell Lung Cancer Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Extensive Disease Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1/Phase 2 · 3 location(s) · InxMed (Shanghai) Co., Ltd. · NCT06030258A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06807632A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relaps
Phase 1/Phase 2 · 12 location(s) · Bristol-Myers Squibb · NCT07325136Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07744256The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
NA · 2 location(s) · University of Colorado, Boulder · NCT07636200Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · 148 location(s) · SWOG Cancer Research Network · NCT06769126A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi
Phase 3 · 164 location(s) · Amgen · NCT07005128A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizum
Phase 1 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT07413042Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cel
Phase N/A · 1 location(s) · Shanghai Chest Hospital of Shanghai Jiao Tong University · NCT07070011Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
Phase 1 · 1 location(s) · University of Texas Southwestern Medical Center · NCT07139990A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05924841Molecular Analysis and Treatment Options of SCLC
Phase N/A · 1 location(s) · Shanghai Chest Hospital · NCT05945745Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT06758700DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carbop
Phase 3 · 242 location(s) · Boehringer Ingelheim · NCT07472517A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combinati
Phase 2 · 62 location(s) · AbbVie · NCT07155174A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD
Phase 2 · 1 location(s) · China Medical University, China · NCT07373964SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Phase 1/Phase 2 · 1 location(s) · SN BioScience · NCT07391813Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Phase 2 · 1 location(s) · Guangzhou Institute of Respiratory Disease · NCT06497530Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Phase 1 · 3 location(s) · Emory University · NCT05244239Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
Phase 2 · 5 location(s) · Universität des Saarlandes · NCT06223711Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Phase 2 · 1 location(s) · Regina Elena Cancer Institute · NCT06771518Adebrelimab + Apatinib in SCLC Maintenance Therapy
Phase 2 · 1 location(s) · Tang-Du Hospital · NCT06475209Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participant
Phase 1 · 1 location(s) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · NCT07231445PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (
NA · 41 location(s) · European Organisation for Research and Treatment of Cancer - · NCT04790253A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants Wit
Phase 1/Phase 2 · 48 location(s) · Merck Sharp & Dohme LLC · NCT06780137A Study of Ivonescimab in First-Line ES-SCLC
Phase 2 · 3 location(s) · Akeso · NCT07245446Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Phase 1/Phase 2 · 17 location(s) · Genprex, Inc. · NCT05703971Lung Cancer Registry
Phase N/A · 3 location(s) · Arbeitsgemeinschaft medikamentoese Tumortherapie · NCT04654364Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Phase 4 · 1 location(s) · Pharmacosmos A/S · NCT05874401Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer
Phase N/A · 3 location(s) · Qingdao Central Hospital · NCT06514118
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.